FDA Guidance and Notices, January 2025: Draft Guidance on AI-Enabled Device Lifecycle Management and Pulse Oximeters
January 7, 2025 brought a large batch of FDA guidance. For device regulatory teams, two drafts matter most: one on lifecycle management and marketing submissions for AI-enabled device software functions, and one on performance testing and labeling for medical pulse oximeters.
On the final side, FDA explained how it reviews PMA and HDE (Humanitarian Device Exemption) applications submitted in modules. On January 30, a safety communication warned of cybersecurity vulnerabilities in certain Contec and Epsimed patient monitors.
Final guidance
- Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers (January 7): Questions and answers on how firms may share scientific information about unapproved uses of approved or cleared products with health care providers. Although final, the PDF is marked "Not for Current Implementation."
- Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act (January 7): Explains how manufacturers notify FDA of a permanent discontinuance or interruption in making a device under section 506J of the FD&C Act.
- Premarket Approval Application and Humanitarian Device Exemption Modular Review (January 13): Describes how PMA and HDE applications can be submitted and reviewed in separate modules.
Draft guidance
- Considerations for Including Tissue Biopsies in Clinical Trials (January 6): Sets out what sponsors should consider before building tissue biopsies into a clinical trial.
- Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations (January 7): Covers how to manage AI-enabled device software functions from development through postmarket use, and what to put in the marketing submission.
- Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products (January 7): Written for drugs and biological products; it is separate from the AI device submission draft above.
- Evaluation of Sex-Specific and Gender-Specific Data in Medical Device Clinical Studies (January 7): The draft as it stood at this point on how to evaluate sex-specific and gender-specific data in device clinical studies.
- Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations (January 7): Covers non-clinical and clinical performance testing, labeling and what to include in premarket submissions.
- Study of Sex Differences in the Clinical Evaluation of Medical Products (January 7): Addresses how to study sex differences when evaluating medical products clinically, devices included.
- Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency (January 7): How to validate certain in vitro diagnostic devices (IVDs) for emerging pathogens when an emergency has been declared under section 564.
- Developing Drugs for Optical Imaging (January 8): A drug development draft that also touches on the imaging devices used with these agents.
In the Federal Register
- Regulatory Hearing Before the Food and Drug Administration; General Provisions; Amendments; Withdrawal (January 17): Withdraws a direct final rule on regulatory hearings before FDA; it sets no new requirements.
Safety communications and other updates
- Medical Device Supply Chain Vulnerabilities and the Public Health Impact They Have on Our Most Vulnerable Patients (January 16): A CDRH statement on supply chain weaknesses and shortages affecting devices for children and other vulnerable patients. Among the gaps it names: the section 506J notification requirement applies only during public health emergencies.
- Update: Evaluation of Airborne Chemicals from Neonatal Incubators - Letter to Health Care Providers (January 16): Testing found no concerning levels of airborne chemicals in newly supplied neonatal incubators for the U.S., so running them for a week before use is no longer necessary.
- Cybersecurity Vulnerabilities with Certain Patient Monitors from Contec and Epsimed: FDA Safety Communication (January 30): Warns of risks of remote control, a backdoor and transmission of patient data, with steps that depend on how the monitors are networked and used for remote monitoring.
Also this month
- January 14: FDA held a webinar on the final guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled device software functions.
Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles